Overview

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Status:
Completed
Trial end date:
2017-06-26
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SciFluor Life Sciences, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions